Martin Maier
Vermögen: - $ am 31.05.2026
Vermögen: - $ am 31.05.2026
Martin Maier currently works at Oligonucleotide Therapeutics Society, Inc., as Director, ProQR Therapeutics NV, as Member-Supervisory Board from 2024, and Alnylam Pharmaceuticals, Inc., as Senior Vice President-Oncology.
Dr. Maier received his doctorate degree in 1997 from Eberhard Karls Universität Tübingen.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 18.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PROQR THERAPEUTICS N.V. | Direktor/Vorstandsmitglied | 22.05.2024 |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2006 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Eberhard Karls Universität Tübingen
Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a non-profit forum for research and development of oligonucleotide therapeutics | Commercial Services |
ProQR Therapeutics NV
ProQR Therapeutics NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company with interest in the discovery and development of therapeutics for the treatment of genetic disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen